Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/212220
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGarcía Gros, Júlia-
dc.contributor.authorCajal Visa, Yolanda-
dc.contributor.authorMarqués Villavecchia, Ana M.-
dc.contributor.authorRabanal Anglada, Francesc-
dc.date.accessioned2024-05-30T11:49:33Z-
dc.date.available2024-05-30T11:49:33Z-
dc.date.issued2024-04-27-
dc.identifier.issn2218-273X-
dc.identifier.urihttp://hdl.handle.net/2445/212220-
dc.description.abstract<p>The problem of antimicrobial resistance is becoming a daunting challenge for the human society and health care systems around the world. Hence, there is a constant need to develop new antibiotics to fight resistant bacteria, among other important social and economic measures. In this regard, murepavadin is a cyclic antibacterial peptide in development. The synthesis of murepavadin was undertaken in order to optimize the preparative protocol and scale-up. In our hands, classical approaches using carbodiimide/hydroxybenzotriazole rendered low yields. In addition, benzotriazole-based reagents have been reported to exhibit explosive properties. The use of the new TBEC carbodiimide and reagents based on OxymaPure<sup>®</sup> and Oxy-B is discussed together with proper use of chromatographic conditions for the adequate characterization of the peptide crudes. Higher yields and purities are obtained with the new reagents compared to traditional protocols. Finally, the antimicrobial activity of the different synthetic batches was tested in three <em>Pseudomonas aeruginosa</em> strains, including highly resistant varieties which consisted of two carbapenem-resistant strains and an extended spectrum ß-lactamase (ESBL) producer. All murepavadin batches yielded the same MIC values, independently of the synthetic approach used, which demonstrates that the chiral integrity of the molecule was preserved throughout the whole synthetic procedure.</p>-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/biom14050526-
dc.relation.ispartofBiomolecules, 2024, vol. 14, num.526, p. 1-12-
dc.relation.urihttps://doi.org/10.3390/biom14050526-
dc.rightscc-by (c) García-Gros J. et al., 2024-
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Biologia, Sanitat i Medi Ambient)-
dc.subject.classificationSíntesi de pèptids-
dc.subject.classificationAntibiòtics-
dc.subject.otherPeptide synthesis-
dc.subject.otherAntibiotics-
dc.titleSynthesis of the antimicrobial peptide murepavadin using novel coupling agents-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec748198-
dc.date.updated2024-05-30T11:49:38Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Biologia, Sanitat i Medi Ambient)

Files in This Item:
File Description SizeFormat 
859832.pdf647.06 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons